Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival June 05, 2026Vol.52 No.22By Jacquelyn Cobb
Trials & Tribulations The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe June 05, 2026Vol.52 No.22By W. Kimryn Rathmell
Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final June 05, 2026Vol.52 No.22By Paul Goldberg and Claire Marie Porter
At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer June 05, 2026Vol.52 No.22By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg
Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.” June 05, 2026Vol.52 No.22By Claire Marie Porter
PodcastThe Directors The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight May 29, 2026Vol.52 No.21By Paul Goldberg and Claire Marie Porter
When CAM is added to standard therapies, survival rates drop, observational study finds May 29, 2026Vol.52 No.21By Jacquelyn Cobb
Trials & Tribulations As rural cancer disparities persist, aligning policy with care delivery models can close the gap May 29, 2026Vol.52 No.21By Matthew L. Anderson
Sponsored UK Markey’s Denise Fabian: Theranostics lets us pair a diagnostic with a radioactive therapeutic that target the same molecule May 29, 2026Vol.52 No.21
